Sotrovimab

Error creating thumbnail:

Sotrovimab.jpg

Sotrovimab is a monoclonal antibody used for the treatment of COVID-19. It is designed to target the spike protein of the SARS-CoV-2 virus, which is responsible for the virus's entry into human cells. Sotrovimab is developed by GlaxoSmithKline and Vir Biotechnology.

Mechanism of Action

Sotrovimab works by binding to the spike protein of the SARS-CoV-2 virus, thereby preventing the virus from attaching to and entering human cells. This action helps to neutralize the virus and reduce the severity of the disease.

Clinical Use

Sotrovimab is authorized for emergency use in several countries for the treatment of mild to moderate COVID-19 in patients who are at high risk of progressing to severe disease, including hospitalization or death. It is administered via intravenous infusion.

Efficacy

Clinical trials have shown that sotrovimab significantly reduces the risk of hospitalization and death in high-risk patients with COVID-19. The antibody has been found to retain activity against multiple variants of the virus, including the Delta variant and Omicron variant.

Side Effects

Common side effects of sotrovimab include infusion-related reactions, such as fever, chills, and headache. Serious adverse events are rare but can include hypersensitivity reactions.

Regulatory Status

Sotrovimab has received Emergency Use Authorization (EUA) from the United States Food and Drug Administration (FDA) and similar authorizations from other regulatory bodies around the world.

See Also

• Monoclonal antibody
• COVID-19
• SARS-CoV-2
• GlaxoSmithKline
• Vir Biotechnology
• Emergency Use Authorization